M. Elkabets

Functional binding of PD1 ligands predicts response to anti-PD1 treatment in cancer patients

The paper develops a method to predict response to anti-PD1 therapy by measuring PDL1 and PDL2 binding functionality, finding it more effective than protein expression alone.

TRAF3 Suppression Encourages B Cell Recruitment and Prolongs Survival of Microbiome-Intact Mice with Ovarian Cancer

This study identifies TRAF3 as a tumor-derived immune suppressor in ovarian cancer, showing its role in inhibiting B-cell infiltration and that microbiota presence is required for B-cell activation and tumor progression.

4EBP1/2 support tumorigenicity and cell survival during energetic stress by translationally regulating fatty acid synthesis

This study shows 4EBP1/2 promote cell survival under glucose starvation by repressing fatty acid synthesis and maintaining redox balance, supporting tumorigenicity in cancer cells.

MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer

This study shows that MEK1/2 inhibition temporarily improves the tumor immune microenvironment, enhancing immunotherapy effectiveness in head and neck cancer by reducing suppressive myeloid cells and boosting CD8+ T cell activity.

Inference of long-range cell-cell force transmission from ECM remodeling fluctuations

This paper introduces a computational method to infer long-range cell-cell force transmission through the extracellular matrix using ECM remodeling fluctuations, demonstrating its effectiveness in fibroblast and cancer cell models.

The AP-1 complex regulates AXL expression and determines sensitivity to PI3Kα inhibition in esophagus and head and neck squamous cell carcinoma

This study shows that AP-1 factors regulate AXL expression, which contributes to resistance to PI3Kα inhibition in ESCC and HNSCC, and that JNK inhibition combined with PI3Kα inhibition enhances anti-tumor effects.